Does Rallies show 13F holders for ORKA?

Yes. Rallies tracks hedge fund and 13F ownership data for ORKA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ORKA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ORKA. It does not provide personalized investment advice.

ORKA (Oruka Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Oruka Therapeutics, Inc. Common Stock (ORKA) is a publicly traded Healthcare sector company. As of May 21, 2026, ORKA trades at $60.67 with a market cap of $3.52B and a P/E ratio of 0.00. ORKA moved +5.49% today. Year to date, ORKA is +125.71%; over the trailing twelve months it is +471.28%. Its 52-week range spans $5.49 to $91.00. Analyst consensus is strong buy with an average price target of $137.25. Rallies surfaces ORKA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ORKA stock?

Hedge funds tracked by Rallies that own ORKA include Viking Global and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Oruka Therapeutics, Inc. Common Stock.

ORKA Key Metrics

Key financial metrics for ORKA
Metric	Value
Price	$60.67
Market Cap	$3.52B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$91.00
52-Week Low	$5.49
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-105.43M
Gross Margin	0.00%

Top Hedge Funds Holding ORKA

Viking Global holds 2.67M shares of ORKA, changed +0.00% as of Mar 31, 2026.
Redmile Group holds 386.96K shares of ORKA, changed -6.01% as of Mar 31, 2025.

Latest ORKA News

Oruka Reports 63.5% PASI 100 Rate and Raises $700M Cash — May 13, 2026
Oruka Therapeutics Prices $700.4M Offer at $72.50 Per Share — Apr 29, 2026
Oruka Therapeutics Files $500M Public Offering with $75M Upsize Option — Apr 27, 2026
Orka Shares Climb 18.9% After 63.5% PASI 100 Trial and $160 Target — Apr 27, 2026
Oruka Therapeutics’ ORKA-001 achieves 63.5% complete skin clearance at week 16 — Apr 27, 2026

Recent ORKA Insider Trades

Agarwal Arjun sold 4.19K (~$244.47K) on May 18, 2026.
Agarwal Arjun sold 4.60K (~$272.26K) on May 18, 2026.
Agarwal Arjun sold 800 (~$48.27K) on May 18, 2026.

ORKA Analyst Consensus

13 analysts cover ORKA: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.25.

Common questions about ORKA

Who owns ORKA stock?: Hedge funds tracked by Rallies that own ORKA include Viking Global and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Oruka Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ORKA?: Yes. Rallies tracks hedge fund and 13F ownership data for ORKA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ORKA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ORKA. It does not provide personalized investment advice.